sastium 100 mg tabletki powlekane
accord healthcare polska sp. z o.o. - sertralinum - tabletki powlekane - 100 mg
aposerta 50 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - sertralini hydrochloridum - tabletki powlekane - 50 mg
aposerta 100 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - sertralini hydrochloridum - tabletki powlekane - 100 mg
sertraline farmax 50 mg tabletki powlekane
neuraxpharm bohemia s.r.o. - sertralinum - tabletki powlekane - 50 mg
sertraline farmax 100 mg tabletki powlekane
neuraxpharm bohemia s.r.o. - sertralinum - tabletki powlekane - 100 mg
aurofena 400 mcg tabletki podpoliczkowe
aurovitas pharma polska sp. z o.o. - fentanylu cytrynian - tabletki podpoliczkowe - 400 mcg
aurofena 100 mcg tabletki podpoliczkowe
aurovitas pharma polska sp. z o.o. - fentanylu cytrynian - tabletki podpoliczkowe - 100 mcg
aurofena 200 mcg tabletki podpoliczkowe
aurovitas pharma polska sp. z o.o. - fentanylu cytrynian - tabletki podpoliczkowe - 200 mcg
sertraline zentiva 25 mg tabletki powlekane
zentiva, k.s. - sertralini hydrochloridum - tabletki powlekane - 25 mg
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.